Synsam is a Swedish eyecare retailer and optician chain, selling prescription eyeglasses, contact lenses and sunglasses through its own store network across the Nordics and beyond, alongside its in-house brands. Its edge is vertical integration: running the optical stores, the eye exams and much of the product range under one roof gives it a 74.7% gross margin, which is the kind of figure that usually signals pricing power in a fragmented, service-heavy retail market. Revenue is growing at 11.2%, and with a 23.4% ROE the business is turning its equity into profit efficiently. The stock trades at 13.8 times earnings, which looks undemanding for a company growing at that pace with a 14.2% operating margin. The data we have does not include the near-term catalyst or margin trend, so that is the first thing to pin down before committing research time.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | kr 64.00 | first publication | kr 55.40 |
| 22 Oct 2026, 14:04 CEST | Rating | Undervalued | first publication | kr 54.90 |
| 22 Oct 2026, 14:04 CEST | Fair value | kr 68.76 | first publication | kr 54.90 |
Answered from Synsam AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| SYNSAM.ST Synsam AB (publ) | kr 55.70 | kr 69 | 19% below | 13.9x | 23.4% | 67 | 63 |
| DYVOX.ST Dynavox Group AB (publ) | kr 71.20 | kr 45 | 59% above | 27.6x | 40.4% | 76 | 51 |
| BONEX.ST Bonesupport Holding AB (publ) | kr 332.60 | - | - | 81.5x | 24.5% | 88 | 72 |
| ALIF-B.ST AddLife AB (publ) | kr 184.20 | kr 133 | 39% above | 35.0x | 11.5% | 54 | 54 |
| ICUI ICU Medical Inc. Common Stock | $166.62 | $111 | 51% above | 134.7x | 1.4% | 43 | 50 |
| 1SXP.DE SCHOTT Pharma AG & Co. KGaA | €25.70 | €17 | 50% above | 28.6x | 14.7% | 69 | 61 |
| ANN.AX Ansell Limited | A$46.27 | A$40 | 16% above | 21.6x | 10.5% | 67 | 75 |
Where SYNSAM.ST ranks against its sector peers on each metric.